InvestorsHub Logo
Followers 216
Posts 32534
Boards Moderated 3
Alias Born 09/10/2000

Re: stupified777 post# 1284

Tuesday, 04/02/2019 1:25:30 PM

Tuesday, April 02, 2019 1:25:30 PM

Post# of 1738
“We believe that the issues cited in the CRL, which were related to concerns over reproducible dose delivery, can be addressed. We look forward to meeting with FDA to gain a full understanding of the Agency’s requirements for approval and remain committed to bringing our novel nasal formulation of metoclopramide to patients,” said Dave Gonyer, President and CEO.

Apparently the market does not agree.

WOW: these babies are volatile...

If I'm reading this right it's not the drug, it's the delivery system...They want consistent and reliable dosing. So I agree with the CEO, shouldn't be too hard to fix...But the market has obviously spoken. -46% as I type this.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent EVOK News